MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i>-mutated advanced pancreatic ductal adenocarcinoma (PDAC).Maahum Mehdi, Mandana Kamgar, James P. Thomas et al.|Journal of Clinical Oncology|2022Cited by 7
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, Thomas McFall, G. Aaron Hobbs et al.|Cancer Research|2025Cited by 3